Europe Life Sciences Weekly Signal #34
Week of 20–26 April 2026
This was a week of arrivals.
Lilly moved to acquire an in vivo CAR-T platform for up to $7 billion. Sanofi posted strong Q1 numbers just before Belén Garijo formally takes over as CEO. Roche grew globally, but Europe remained the softer regional signal. Novartis withdrew a Pluvicto EU expansion application after CHMP feedback on evidence design. NICE’s higher cost-effectiveness thresholds are now live in the UK. EUDAMED’s first mandatory modules are no longer a distant regulatory calendar item. And Brussels put more money behind health AI deployment infrastructure.
The connecting thread is simple: the strategic decisions were made months ago. What arrived this week was the operating consequence.
For commercial leaders, that matters. The advantage is no longer in being able to announce innovation. It is in having the evidence, access, data, governance and deployment model ready when innovation becomes executable.
Commercial Moves
Lilly buys Kelonia and the signal is manufacturing architecture, not just oncology M&A
Eli Lilly agreed to acquire Kelonia Therapeutics for up to $7 billion in cash, including $3.25 billion upfront and further clinical, regulatory and commercial milestone payments. Kelonia’s lead programme, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy in Phase 1 for relapsed or refractory multiple myeloma. Its proprietary in vivo gene placement system is designed to allow the patient’s own body to generate CAR-T cells.
That makes this more than a large oncology transaction. It is a bet on changing the operating model of cell therapy.
Current ex vivo CAR-T models are clinically powerful but commercially and operationally hard: leukapheresis, centralised manufacturing, long production timelines, specialist logistics, complex capacity planning and high treatment costs. An in vivo approach, if it proves clinically and commercially viable, would attack some of the structural bottlenecks that limit scale.
The commercial implication is uncomfortable for companies investing heavily in today’s cell-therapy infrastructure. The question is not only whether the science works. It is whether the manufacturing and delivery architecture being built now will still be the right one in three to five years.
For European biotech, the signal is also familiar: platform science can be built globally, but ownership of the commercial scaling path often concentrates quickly in large pharma. That is not new. It is just becoming more expensive.
Sanofi posts a strong Q1 and hands Garijo a clean handover
Sanofi reported Q1 2026 sales growth of 13.6% at constant exchange rates, with pharma launch sales up 49.6% to €1.2 billion and Dupixent sales up 30.8% to €4.2 billion. Business EPS rose 14.0% at CER to €1.88. The company also reported selling and general expenses of €2.3 billion, up 11.6%, mainly due to recent acquisitions, and reaffirmed 2026 guidance for high single-digit sales growth at CER, with business EPS expected to grow slightly faster than sales.
The timing matters. Belén Garijo is due to take up the Sanofi CEO role after the company’s Annual General Meeting on 29 April 2026, following the transition from Paul Hudson and interim CEO Olivier Charmeil.
The easy read is “strong quarter before new CEO”. The more useful read is that Sanofi’s growth story now depends on whether launch performance, Dupixent expansion and recently acquired assets can keep outpacing the cost and complexity of integration.
That is the commercial transformation question inside the earnings release. Large pharma is no longer simply trying to launch more products. It is trying to build a launch engine that can absorb acquisitions, prioritise evidence, sequence markets, govern content and support medical-commercial alignment without turning every launch into a heroic manual effort.
Garijo inherits momentum. The first question is whether she turns that momentum into a more durable operating model.
Roche grows globally but Europe is where the gap shows
Roche reported Q1 2026 group sales of CHF 14.7 billion, up 6% at constant exchange rates and down 5% in Swiss francs due to currency effects. The Pharmaceuticals Division grew 7% at CER to CHF 11.5 billion, while diagnostics grew 3% at CER to CHF 3.3 billion.
The regional split is the useful signal. Roche’s pharmaceutical sales in Europe were down 1% at CER, while Japan grew 14% and the International region grew 16%. Diagnostics in EMEA grew 3% at CER.
Roche is growing, but the global picture masks an uncomfortable European read. When a company with Roche’s breadth shows this pattern, the question for European leaders is not “what went wrong in one market?” It is whether the region’s access dynamics, price pressure and institutional decision-making are making launch sequencing more important than ever.
The company’s product mix also shows how much of modern pharma growth depends on disciplined franchise execution. Ocrevus, Hemlibra, Vabysmo, Xolair and Phesgo remain central growth engines. That is strong, but it also raises the strategic bar for every new launch trying to earn its place in the commercial portfolio.
Europe strategy is becoming less about coverage and more about prioritisation: which markets first, with what evidence, through which access route, and with how much shared operating support.
This is where commercial excellence, market access and finance need to sit closer together. In a slower-growth region, the cost of mediocre sequencing rises quickly.
Regulation and Market Access
EMA’s April CHMP meeting shows Europe’s dual character: high-science access and tougher evidence discipline
EMA’s CHMP recommended five new medicines for approval at its 20–23 April meeting, alongside positive recommendations for extensions of therapeutic indication. The new medicine recommendations included Sanofi’s Cenrifki for non-relapsing secondary progressive multiple sclerosis, Novartis’ Itvisma for spinal muscular atrophy, Redemplo for familial chylomicronaemia syndrome, a ranibizumab biosimilar and generic palbociclib.
The count matters less than the mix.
Rare disease, progressive neurology, gene therapy, biosimilar competition and oncology generics all moved through the same regulatory window. That is Europe in miniature: high-science launches, access-sensitive therapies and margin-compressing competition now coexist by default.
The operating model has to be able to support all three. Most organisations are still better at one than the others.
Sanofi’s Cenrifki opinion moves MS further into the progression conversation
Sanofi received a positive CHMP opinion for Cenrifki, for adults with secondary progressive multiple sclerosis without relapses in the last two years. Sanofi said the recommendation was based on the HERCULES phase 3 study and framed disability progression as a significant unmet need in this stage of MS care.
Commercially, this matters because it pushes the MS conversation further away from visible relapse control and towards slower, harder-to-measure progression.
That changes the launch model. The field discussion becomes more educational. The evidence narrative becomes more nuanced. Patient identification becomes more important. Access teams need to explain value in outcomes that may not be as immediate or intuitive as relapse reduction.
For transformation leaders, this is exactly where medical, access, commercial, analytics and content teams need to operate as one system. Otherwise, the market receives fragments: one evidence story, one field story, one access story, and one content engine pretending those are aligned.
Novartis gets an Itvisma win, and a Pluvicto evidence reminder
Novartis received a positive CHMP opinion for Itvisma in spinal muscular atrophy. The company said a European Commission decision is expected in approximately two months. If approved, Itvisma would be a one-time gene replacement therapy for children aged two and older, teenagers and adults living with SMA in the EU.
The same CHMP cycle also carried a very different signal. Novartis withdrew its EMA application to expand Pluvicto into pre-chemotherapy PSMA-positive metastatic castration-resistant prostate cancer after CHMP feedback that the committee would not support the application based on the control arm used in the PSMAfore study. Novartis said the withdrawal was not related to Pluvicto’s quality, efficacy or safety and does not affect ongoing trials, approved indications or pending regulatory submissions inside or outside the EU.
That contrast is useful.
Europe is not anti-innovation. It is increasingly exacting about evidence architecture. The same PSMAfore data supported approvals in the US, Japan and China; in Europe, the control-arm design did not pass CHMP scrutiny for the proposed expansion.
Comparator choice, endpoint relevance, trial design, real-world evidence strategy and access narrative are now commercial design decisions, not late-stage technical details.
The old sequence — clinical first, access later, commercial last — is becoming expensive theatre.
NICE’s revised thresholds are live — and UK market access just became more political
NICE confirmed that its standard cost-effectiveness threshold is moving from £20,000–£30,000 to £25,000–£35,000 per quality-adjusted life year gained, with the new value-for-money thresholds being applied from April 2026. NICE said the increase is expected to allow recommendations for an additional three to five medicines or indications per year.
This is UK-specific, but strategically relevant across Europe.
The threshold increase does not remove the access challenge. It changes the negotiation environment. It gives some products more room, but it also makes the pricing and policy context more visible. NICE stated openly that government decides the level of health spend in the UK, while NICE applies the new thresholds through its independent committees.
For market access leaders, the important point is not simply that the threshold moved. It is that one of Europe’s most influential HTA systems is now more visibly connected to industrial policy, fiscal policy and pharmaceutical competitiveness.
That makes launch planning more strategic and more political. Lovely. Just what everyone needed, yet another stakeholder map with teeth.
EUDAMED is now an operating-model deadline, not a regulatory footnote
The first four EUDAMED modules become mandatory on 28 May 2026: Actor Registration, UDI/Device Registration, Notified Bodies and Certificates, and Market Surveillance. The European Commission confirmed that the mandatory-use date follows the November 2025 functionality notice and six-month transition period.
This is not a soft signal. It is an operating-model readiness test.
For medical device manufacturers, EUDAMED readiness is not only about regulatory affairs uploading data into a system. It touches portfolio data quality, UDI governance, economic operator coordination, certificates, market surveillance processes, local affiliates and distributor workflows.
The commercial risk is obvious: if data, registration and internal ownership are not ready, the bottleneck does not stay neatly inside regulatory. It can affect launch timing, market placement, distributor confidence and commercial planning.
EUDAMED has been delayed often enough that some organisations learned the wrong lesson: “this can wait.” That lesson is now expiring.
EMA’s breakthrough-device pilot points to a more structured EU pathway for high-risk innovation
EMA is set to launch a pilot programme on 28 April 2026 offering free expert-panel support to selected manufacturers of high-risk breakthrough medical devices. The pilot will provide advice on possible breakthrough status and implementation guidance for designated breakthrough devices.
This is a quiet but important MedTech signal.
Europe has often struggled to combine rigorous device oversight with faster support for genuinely high-value innovation. The breakthrough-device pilot is not a full solution, but it suggests a more structured route for manufacturers trying to bring high-risk, high-potential devices and IVDs through the system.
For commercial teams, the implication is familiar: regulatory strategy and market access strategy need to be designed together. A faster or better-supported regulatory pathway does not automatically create adoption. It only creates the possibility of adoption — if the clinical evidence, health-economic argument and go-to-market model are ready.
AI and Digital Signals
The EU is funding health AI deployment, not just AI rhetoric
The European Commission opened seven Digital Europe Programme calls worth €63.2 million to support AI in health, digital health, digital skills and online safety. The package includes €9 million for AI-powered image screening in medical centres and €24 million for digital health services and systems under the European Health Data Space.
The more specific imaging call will fund two large-scale pilots of cloud-based AI and GenAI systems for medical imaging, covering modalities including MRI, CT, X-ray, PET and ultrasound.
This is the right kind of AI signal: deployment settings, clinical workflow, health-data infrastructure, compliance tools and European Health Data Space alignment.
It is not enough money to transform the market on its own. But it is enough to show where policy is pointing. Europe is trying to move health AI from demo environment to clinical-operational environment.
The bottleneck will not be model performance alone. It will be procurement, validation, workflow integration, liability, data access, clinical adoption and whether hospitals have the operating capacity to absorb another “transformative” tool without breaking radiology twice.
DMEA shows digital health buyers moving from features to deployment architecture
DMEA 2026 ran in Berlin from 21–23 April, bringing together around 900 exhibitors, more than 20,500 visitors and hundreds of speakers across Europe’s digital health ecosystem. The programme sat directly inside the current European conversation: EHDS, AI in clinical workflows, interoperability, cybersecurity, hospital digitisation and sovereign digital infrastructure.
DMEA is not important because every announcement there changes the market. Most do not. It is important because it reveals what buyers are asking.
The question in digital health is moving from “what does the platform do?” to “how does it integrate with our existing infrastructure, workflows and procurement reality?” That is the commercial maturity shift. In 2026, European digital health companies are no longer just selling capability. They are selling deployability.
That is the same transition pharma commercial transformation went through years ago. Product capability gets you attention. Deployment architecture gets you adoption.
AcuityMD brings agentic AI into MedTech commercial infrastructure
AcuityMD raised $80 million in Series C funding, introduced AcuityAI, and said it is valued at $955 million. The company says it supports 16 of the top 20 MedTech companies and has helped customers identify more than $34 billion in pipeline.
This is a US platform story, but the commercial problem is highly relevant to Europe.
MedTech commercial teams are dealing with fragmented market data, changing reimbursement, hospital consolidation, complex buying centres, procedure-level variation and field teams expected to act with more context than their systems provide. That is exactly the problem commercial AI platforms are trying to solve.
The risk is predictable: agentic AI will be sold as sales productivity. The real value, if it comes, will be commercial decision infrastructure — who to prioritise, why, with what evidence, in which account, under what access constraints.
That requires more than a chatbot with a territory plan. It requires a data model, governance model and decision model that commercial teams actually trust.
Money Flows
European digital health funding is maturing, not simply shrinking
Galen Growth reported that European digital health ventures raised $1.2 billion across 67 VC deals in Q1 2026, down 44% in funding and 46% in deal count versus Q1 2025. But the average deal size rose to $21.1 million, with the quarter showing a stronger tilt towards larger, later-stage rounds. The report also pointed to 113 strategic partnerships, with healthcare providers representing the largest industry share.
That is the signal: fewer bets, larger cheques, more provider validation.
The European digital health market is no longer being rewarded for “platform potential” in the abstract. Capital is concentrating around companies that can show workflow fit, clinical relevance, evidence quality and credible routes to scale.
For pharma and MedTech partners, this changes the scouting filter. The right question is no longer “is this innovative?” It is: can this asset survive procurement, evidence review, integration and adoption inside a real health system?
If not, it is not a strategic partnership. It is another pilot with a charming deck.
Kurma closes Biofund IV at €215 million
Kurma Partners, part of Eurazeo, closed Biofund IV at €215 million. The fund has already completed 11 investments and plans around 20 in total, with Kurma’s total assets under management across all franchises now reaching €1 billion.
This is quieter than a large pharma acquisition, but still relevant.
Europe continues to raise serious life sciences capital, but the bar is not getting lower. Investors are still backing science, especially where company creation, translational path and syndicate strength are credible. The lesson for early-stage companies is discipline. The lesson for pharma is optionality.
High-quality European science remains investable. It just has to work harder to look executable.
Market Access Pressure
European launch economics are becoming board-level again
Reuters reported Roche CEO Thomas Schinecker warning that Europe risks falling further behind the US and China in pharmaceutical innovation because of bureaucracy and government policies. The report also noted that Roche and Sanofi still intend to launch new medicines in Europe, while industry leaders weigh pricing dynamics and the effect of US most-favoured-nation policy.
The useful reading is not “industry complains about pricing”. That would be a short newsletter and a dull one.
The real signal is that launch sequencing, European price corridors and global reference-pricing exposure are moving back into strategic centre stage. Commercial leaders in Europe will need to operate closer to access, policy and finance.
Market access can no longer be treated as a downstream negotiation. It probably stopped being one years ago. 2026 is just making it harder to pretend otherwise.
What Leaders Should Watch?
Evidence design is becoming commercial design.
Platform M&A is now a race for operating architecture.
Sanofi’s new CEO will set the tempo for the next EMEA commercial cycle.
European growth will require sharper sequencing.
AI funding is shifting towards implementation infrastructure.
Regulatory deadlines are becoming commercial deadlines.
Practitioner’s Lens
This week’s pattern is structural, not episodic.
Lilly did not move on Kelonia because cell therapy suddenly became interesting. It moved to own an operating architecture that may reduce some of the friction in today’s CAR-T model. Sanofi’s Q1 was not only a strong earnings update. It was a handover point between one strategic cycle and the next. Roche’s Q1 showed that Europe remains commercially harder than other regions. EMA’s CHMP output showed access momentum, but the Pluvicto withdrawal reminded everyone that evidence architecture still decides what Europe will accept. NICE and EUDAMED showed the same thing from different directions: policy decisions eventually become operating deadlines.
This is the tempo that matters for life sciences leaders now.
The organisations best positioned today are not the ones with the most innovation language. They are the ones that made infrastructure and governance decisions months ago: EUDAMED data architecture, NICE pricing models, evidence design, market sequencing, digital health deployment playbooks, AI governance and commercial decision infrastructure.
The ones scrambling are the ones that treated these as future problems.
That is where transformation work actually lives: in the gap between strategic intent and operating model readiness. The gap does not close because a strategy deck says it should. It closes when someone builds the system that makes the strategy executable.
One Thing To Remember
In 2026, the strategic question is no longer whether Europe can innovate.
It is whether European life sciences organisations can turn innovation into evidence, access, adoption and commercial impact fast enough to stay relevant.
